Open AccessHuman Amniotic Mesenchymal Stem Cells Inhibit aGVHD by Regulating Balance of Treg and T Effector Cells
Author(s) -
Ya Gao,
Weiru Li,
Xiaoyin Bu,
Ying Xu,
Shengchun Cai,
Jinman Zhong,
Meixue Du,
Haitao Sun,
Liping Huang,
Yongjian He,
Xiumei Hu,
Qifa Liu,
Hua Jin,
Qian Wang,
Baohong Ping
Publication year - 2021
Publication title -
journal of inflammation research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.656
H-Index - 33
ISSN - 1178-7031
DOI - 10.2147/jir.s323054
Subject(s) - mesenchymal stem cell , immunology , cell therapy , stem cell , amniotic epithelial cells , medicine , homing (biology) , bone marrow , transplantation , peripheral blood mononuclear cell , cd8 , haematopoiesis , biology , immune system , adult stem cell , pathology , endothelial stem cell , in vitro , microbiology and biotechnology , ecology , biochemistry
Acute graft versus host disease (aGVHD) remains a leading cause of transplant-related mortality following allogeneic haematopoietic cell transplantation (allo-HCT). Human amniotic mesenchymal stem cells (hAMSCs) are a novel mesenchymal stem cells (MSCs), which have stronger proliferation and immunomodulatory ability compared with bone marrow mesenchymal stem cells (BM-MSCs). Besides, as the amniotic membrane is often treated as medical waste after delivery, hAMSCs can be obtained conveniently and noninvasively. The aim of this study was to explore the therapeutic efficacy and underlying mechanisms of hAMSCs transplantation for the humanized aGVHD mouse model.